J Korean Cancer Assoc.  1997 Apr;29(2):332-339.

Comparison of Tropisetron with Ondansetron in the Prevention of Cisplatin-induced Nausea and Vomiting

• Lee KS
• Han JY
• Moon H
• Lee BK
• Cho SG
• Jin JY
• Hong YS
• Kim HK

Abstract

PURPOSE: Tropisetron (Nabovan (R)) is a new specific 5-HT3 receptor antagonist with a long terminal half life in plasma and high bioavailability after oral intake. We compared the antiemetic effectiveness and tolerability of tropisetron with ondansetron in the highly emetogenic chemotherapy (including cisplatin > or =50 mg/m2).
MATERIALS AND METHODS
Thirty-nine patients were administered in a randomized, multicenter, open, cross-over study and received either tropisetron plus dexamethasone (n=31) or ondansetron plus dexamethasone (n=34) during six days of two successive cycles of chemotherapy.
RESULTS
Total control of vomiting with either Ondansetron or tropisetron was 94.2 % vs 93.5 % in D1 (P=0.157); 90.6 % vs 93.1 % in D2 (P=0.18); 90.3 % vs 93.1 % in D3 (P=0.655); 96.4% vs 96.4 % in D4 (P=0.157); 96.4 % vs 100 % in D5 (P=0.317); 96.4 % vs 100% in D6, respectively. The duration of nausea showed significant decreasements in tropisetron at D5 and D6 (P=0.025, P=0.03, respectively), but the severity of nausea and performance status showed no significance. Headache and constipation were the most common side effects in both groups.
CONCLUSION
There was no significant difference in efficacy and tolerability between tropisetron and ondansetron in the cisplatin-based chemotherapy.

Keyword

Nausea; Vomiting; Cisplatin; Tropisetron; Ondnasetron

MeSH Terms

Antiemetics
Biological Availability
Cisplatin
Constipation
Cross-Over Studies
Dexamethasone
Drug Therapy
Half-Life
Headache
Humans
Nausea*
Ondansetron*
Plasma
Receptors, Serotonin, 5-HT3
Vomiting*
Antiemetics
Cisplatin
Dexamethasone
Ondansetron
Receptors, Serotonin, 5-HT3